Scientific Advisory Board
Dr. Demetri's research and clinical interests have focused on the development of targeted therapies for sarcomas and other solid tumors. The contributions of Dr. Demetri and his colleagues at Dana-Farber/Harvard Cancer Center have led to the development of cancer treatments such as Gleevec and Sutent. Dr. Demetri received an undergraduate degree from Harvard University and a medical degree from Stanford University School of Medicine. After completing Internal Medicine residency and chief residency at the University of Washington Hospitals in Seattle, Washington, he pursued a fellowship in Medical Oncology at Dana-Farber Cancer Institute and Harvard Medical School, where he has served as an attending physician since 1989. Dr. Demetri serves as co-chair of the Medical Advisory Board for the Sarcoma Alliance for Research through Collaboration (SARC) and Executive Director for Clinical and Translational Research in the Ludwig Center for Cancer Research, the largest philanthropic organization supporting cancer research.
Bob Jackson trained as a pharmacologist (Ph.D. from Institute of Cancer Research, London and Surrey), and following postdoctoral work at Yale University and Scripps Clinic, he held academic positions at the Institute of Cancer Research and Indiana University. Industry positions included Director of Chemotherapy at Warner-Lambert/Parke Davis and Group Director, Cancer Research, at Du Pont. He held the position of Head of R&D at four biotech companies (Agouron, Chiroscience, Celltech-Chiroscience, Cyclacel). In total he managed the development of 25 drugs into clinical trials, five of which are currently marketed. He is sole author of two books, and author or co-author of over 170 other publications. He has been member and chair of several study sections and other advisory committees for NCI, NIH, the UK government and the European Union. He is currently the chairman of the Discovery Committee of Cancer UK.
Dr. Wolchok is Associate Attending Physician at Memorial Sloan-Kettering Cancer Center with expertise in the treatment of metastatic melanoma. He is also the co-director of the Swim Across America laboratory at MSKCC, one of the foremost immunotherapy and melanoma research groups in the country. His specific area research interest is the preclinical and early clinical development of novel immunologic therapies. Most recently, Dr. Wolchok has initiated several clinical trials using plasmid DNA vaccines for patients with melanoma. He has been involved in the development of the DNA vaccine program at every level— from initial studies in mouse models, through all levels of regulatory review and now as Principal Investigator of the clinical trials. Dr. Wolchok has authored numerous articles concerning DNA vaccines, cytokine biology and clinical care of melanoma and co-authored two chapters in the definitive textbook, Cutaneous Melanoma. Dr. Wolchok is also co-editor of the journal Cytotherapy. Most recently, Dr. Wolchok was appointed to be Associate Director of the Ludwig Center for Cancer Immunotherapy at MSKCC as well as Director of Immunotherapy Clinical Trials.